Literature DB >> 34196265

Dexmedetomidine inhibits inflammatory response and oxidative stress through regulating miR-205-5p by targeting HMGB1 in cerebral ischemic/reperfusion.

Jun-Jun Yang1, Yan-Hong Zhao1, Ke-Wen Yin1, Xiao-Qing Zhang1, Jianhui Liu1.   

Abstract

OBJECTIVE: To investigate effects of dexmedetomidine (DEX) on miR-205-5p/HMGB1 axis in cerebral ischemic/reperfusion (I/R) injury.
METHODS: Both in vivo I/R rat model and in vitro hypoxia/reoxygenation (H/R) cell model using rat hippocampal neurons cells were established. miR-205-5p was overexpressed or inhibited by transfection of miR-205-5p mimics or inhibitor. HMGB1 was overexpressed by transfection overexpression plasmids (OE-HMGB1). TTC staining was used for measurement of infraction volume. Oxidative stress was evaluated by measurement of reactive oxygen species (ROS), malondialdehyde (MDA) and superoxide dismutase (SOD) and inflammation was evaluated by measurement of IL-1β, IL-6 and TNF-α. Dual luciferase reporter assay was performed to confirm binding between miR-205-5p and HMGB1. The expression levels of miR-205-5p, and HMGB1 were measured using RT-qPCR. Western blotting was used to test the protein expression levels of HMGB1, nuclear factor erythroid 2-related factor 2 (Nrf2), glutathione peroxidase (GPx), glutathione reductase (GR), heme oxygenase 1 (HO-1) and catalase (CAT).
RESULTS: Treatment of DEX significantly reduced brain infraction volume, decreased Longa's neurological function score and inhibited oxidative stress and inflammation in brain tissues of I/R rats, which were all reversed by inhibition of miR-205-5p. Both treatment of DEX or overexpression of miR-205-5p restricted oxidative stress and inflammation in H/R rat hippocampal neurons cells. The inhibition of miR-205-5p reversed the effects of DEX, while the overexpression of HMGB1 reversed the effects of miR-205-5p overexpression in H/R rat hippocampal neurons cells. Dual luciferase reporter assay showed miR-205-5p directly targeted HMGB1.
CONCLUSION: DEX improved I/R injury by suppressing brain oxidative stress and inflammation DEX improved I/R injury by suppressing brain oxidative stress and inflammation through activating miR-205-5p/HMGB1 axis through activating miR-205-5p/HMGB1 axis.

Entities:  

Keywords:  Dexmedetomidine; HMGB1; inflammation; miR-205-5p; oxidative stress

Mesh:

Substances:

Year:  2021        PMID: 34196265     DOI: 10.1080/08923973.2021.1942901

Source DB:  PubMed          Journal:  Immunopharmacol Immunotoxicol        ISSN: 0892-3973            Impact factor:   3.712


  5 in total

1.  MicroRNA-205-5p plays a suppressive role in the high-fat diet-induced atrial fibrosis through regulation of the EHMT2/IGFBP3 axis.

Authors:  Zezhou Xiao; Yu Xie; Fangze Huang; Jie Yang; Ximao Liu; Xuefeng Lin; Peng Zhu; Shaoyi Zheng
Journal:  Genes Nutr       Date:  2022-07-20       Impact factor: 4.423

2.  Phosphatidylethanolamine-binding protein 1 (PEBP1) mediates the regulatory role of microRNAs (miRNAs)-205-5p in degranulation and histamine release.

Authors:  Yuting Kuang; Binya Hu; Min Huang; Sijun Zhao; Xionghui Wu; Mengping Zhang; Zhong Xie
Journal:  Bioengineered       Date:  2022-05       Impact factor: 6.832

Review 3.  The Role of miRNAs in Dexmedetomidine's Neuroprotective Effects against Brain Disorders.

Authors:  Codrin-Constantin Burlacu; Maria-Adriana Neag; Andrei-Otto Mitre; Alexandru-Constantin Sirbu; Andrei-Vlad Badulescu; Anca-Dana Buzoianu
Journal:  Int J Mol Sci       Date:  2022-05-13       Impact factor: 6.208

4.  Sevoflurane protects against cerebral ischemia/reperfusion injury via microrna-30c-5p modulating homeodomain-interacting protein kinase 1.

Authors:  Guoning Su; Yan Qu; Gang Li; Min Deng
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  Danhong injection represses diabetic retinopathy and nephropathy advancement in diabetic mice by upregulating microRNA-30d-5p and targeting JAK1.

Authors:  Wei Deng; Dan Huang; HongWu Xie; LiMin Wang; Qun Shen; RongRong Zeng; YuanLian Huang; JianHua Li; Bo Yang
Journal:  Bioengineered       Date:  2022-04       Impact factor: 6.832

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.